MedPath

Effect of an Exercise on Serum Uncoupling Protein-1 Level and the Role of Uncoupling Protein-1-3826 A/G Polymorphism

Not Applicable
Completed
Conditions
Irisin
Uncoupling Protein-1
Polymorphism, Restriction Fragment Length
Registration Number
NCT04156113
Lead Sponsor
Eastern Mediterranean University
Brief Summary

This study aims to determine the effect of an acute maximal exercise on serum uncoupling protein-1, irisin, interleukin 6 levels, and on blood lipid and lipoprotein concentrations. This study also evaluates the role of uncoupling protein-1-3826 A/G polymorphism on this eventual effect.

Therefore, this study hypothesizes that:

H01: Sedentary people and athletes' serum uncoupling protein 1, irisin, and interleukine 6 levels are different before and after an acute maximal exercise.

H02: Sedentary people and athletes' basal serum uncoupling protein 1 levels are associated with uncoupling protein 1-3826 A/G polymorphism.

H03: Uncoupling protein 1-3826 A/G polymorphism has a modifying role in the effect of maximal exercise on serum uncoupling protein 1 levels.

H04: Sedentary people and athletes' basal serum lipid and lipoprotein levels are associated with uncoupling protein 1-3826 A/G polymorphism.

H05: Uncoupling protein 1-3826 A / G polymorphism has a modifying role in the effect of maximal exercise on serum lipid and lipoprotein levels.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
86
Inclusion Criteria
  • Athletes group:

    • Must be basketball, or volleyball, or handball players.
    • Must be subjects who have been training regularly for at least 3 months.
  • Sedentary group:

    * Must be subjects who have not been training regularly for at least 3 months.

  • For both groups:

    • Healthy.
    • Non obese (body mass index < 30).
    • Aged between 18 and 35 years.
Exclusion Criteria
  • For both groups:

    • Being regular consumer of cigarettes, alcohol, drugs and antioxidant substances.
    • Being obese (body mass index > 30).
    • Having an acute or chronic injury which is limiting physical performance.
    • Having a disease (anemia, infection...) detected from the biochemical analysis of the blood samples.
    • Being injured or sick during the study.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change from the baseline serum uncoupling protein 1 level at 3 minutes post Yo-Yo intermittent recovery test (level 1)15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)

Volunteers' postprandial venous blood samples were taken 15 minutes before the Yo-Yo intermittent recovery test (level 1) and 3 minutes post test. Uncoupling protein 1 analyzes were performed in the laboratory.

Change from the baseline serum irisin level at 3 minutes post Yo-Yo intermittent recovery test (level 1)15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)

Volunteers' postprandial venous blood samples was taken 15 minutes before the Yo-Yo intermittent recovery test (level 1) and 3 minutes post test. Irisin analyzes were performed in the laboratory.

Uncoupling protein-1-3826 A/G polymorphism determination15 minutes before the Yo-Yo intermittent recovery test (level 1)

Volunteers' postprandial venous blood samples were taken 15 minutes before the Yo-Yo intermittent recovery test (level 1). Polymorphism was determined in the laboratory.

Secondary Outcome Measures
NameTimeMethod
Change from the baseline serum interleukin-6 level at 3 minutes post Yo-Yo intermittent recovery test (level 1)15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)

Volunteers' postprandial venous blood samples was taken 15 minutes before the Yo-Yo intermittent recovery test (level 1) and 3 minutes post test. Interleukine-6 analyzes were performed in the laboratory.

Change from the baseline serum nitric oxide level at 3 minutes post Yo-Yo intermittent recovery test (level 1)15 minutes before and 3 minutes after the Yo-Yo intermittent recovery test (level 1)

Volunteers' postprandial venous blood samples was taken 15 minutes before the Yo-Yo intermittent recovery test (level 1) and 3 minutes post test. Nitric oxide analyzes were performed in the laboratory.

Trial Locations

Locations (1)

Ege University Faculty of Sport Sciences

🇹🇷

Izmir, Turkey

Ege University Faculty of Sport Sciences
🇹🇷Izmir, Turkey

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.